Trefoil provided an update on the company and its clinical program for TTHX1114 at the inaugural Eyecelerator 2020 virtual conference on November 6. TTHX1114 is the company’s first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases.
Read More
Media
All news
November 2, 2020
Trefoil Therapeutics to Present Update on Regenerative Treatments for Corneal Diseases
San Diego, CA – November 2, 2020 – Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference. TTHX1114 is the company’s first-in-class, engineered fibroblast growth
Read MoreAugust 19, 2020
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells San Diego, CA – August 19, 2020 – Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast
Read MoreMay 17, 2020
A Bell-Shaped Dose Response of Topical FGF-1 in Dermal Wound Healing of Aged Female BALB/cByJ Mice, Hagerott, B.N., Blumstein, A.J., McGarry, L.E., Cohen, H.M., Tenorio, C.A., Powell, B.D., Nagy, T. and Blaber, M. Journal of Proteins and Proteomics (2020)
May 7, 2020
ARVO 2020: Proliferation of Human Corneal Endothelia in Organ Culture
Trefoil Therapeutics presents the proliferation of human corneal endothelia in organ culture stimulated by engineered human fibroblast growth factor 1 (FGF1) derivative TTHX1114
Read MoreMay 7, 2020
ARVO 2020: Accelerated Healing of Corneal Lesions
Trefoil Therapeutics presents accelerated healing of corneal endothelial lesions by engineered fibroblast growth factor at ARVO 2020.
Read MoreFebruary 10, 2020
Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Experienced clinical development executive to lead the TTHX1114 clinical study in corneal endothelial disease.
Read MoreFebruary 4, 2020
Trefoil Therapeutics Selects AGB Biologics tp Supply Lead Compound TTHX1114
AGC selected based on their proven cGMP capabilities as a manufacturer of protein based therapeutics.
Read MoreJuly 16, 2019
Lead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020.
Read MoreMay 17, 2019
Proliferation of Human Corneal Endothelia in Organ Culture Stimulated by Wounding and the Engineered Human Fibroblast Growth Factor 1 Derivative TTHX1114, David Eveleth, Sarah Pizzuto, Jessica Weant, Jennifer Jenkins-Eveleth, and Ralph A. Bradshaw Journal of Ocular Pharmacology and Therapeutics Ahead of Print (2020)